Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Williamsville, NY, Jan.  13, 2020  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.

22nd Century Group Appoints New Director and New Chairman

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health’ FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health’

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

Williamsville, NY, Dec.  13, 2019  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management.

22nd Century Group Announces Management Changes

22nd Century Group Inc (NYSE: XXII) a plant biotechnology company focused on tobacco and cannabis plant research, on Wednesday announced the initial closing of an investment in Panacea Life Sciences Inc, a company specialized in CBD.

22nd Century Enters CBD Space With $24M Investment In Panacea

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

GW Pharmaceuticals

Which stock wins in a matchup between these two cannabis-focused biotechs?

Better Buy: GW Pharmaceuticals vs. 22nd Century Group

Canopy Growth

Innovative Industrial Properties

Constellation Brands

Trulieve Cannabis Corp.

Put in another context, these are the only six pot stocks that rose last month.

The 6 Best Marijuana Stocks in September

Last month was a rough one for most pot stocks. But these three managed to deliver gains despite the overall malaise.

3 Best Marijuana Stocks of September -- Are They Buys Now?

Aphria

Shopify

Zynerba Pharmaceuticals

Despite another miserable month for marijuana stocks, these companies managed to buck the trend.

Only These 10 Pot Stocks Ended August Higher

Most pot stocks performed poorly last month, but not these three highfliers.

3 Best Marijuana Stocks of August -- Are They Buys Now?

President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share.

22nd Century Group Inc (XXII) President and CEO Clifford B Fleet Bought $190,000 of Shares

As of late, it has definitely been a great time to be an investor 22nd Century Group.

Will 22nd Century Group Continue to Surge Higher?

22nd Century Group's tobacco business still looks like a big ball of problems.

XXII: Hypeless Hemp Helps, We Hope

22nd Century Group, Inc. (XXII) CEO Cliff Fleet on Q2 2019 Results - Earnings Call Transcript

British American Tobacco

Altria

Philip Morris

Turning Point Brands

Universal Corp

Vector Group

There aren't a huge number of U.S.-listed stocks with a tobacco focus, but these companies still combine to be a force in the global industry.

The 9 Biggest Tobacco Stocks

Scotts Miracle-Gro

Only around 1 in 4 marijuana stocks ended the second quarter higher.

These Are the Pot Stocks That Rose in the Second Quarter

The grass may not be greener with these particular pot stocks.

3 Marijuana Stocks to Avoid Like the Plague in May

HEXO Corp

Despite a rare down month for pot stocks as a whole, these 10 companies finished April higher by at least 15%.

The 10 Best Marijuana Stocks in April

Neptune Wellness Solutions Inc.

These pot stocks soared last month, and two still look like great picks for investors.

5 Best Pot Stocks in April -- Are They Buys Now?

The green rush went up in smoke for shareholders in these five marijuana stocks.

These 5 Pot Stocks Lost at Least 15% in the First Quarter

Insys Therapeutics

There are some very familiar marijuana stocks among this bunch of losers.

News for 22nd Century Group Stock (XXII)